Javascript must be enabled to continue!
Mucosal Healing Research Advances of Inflammatory Bowel Disease
View through CrossRef
Inflammatory bowel disease (IBD) refers to a group of chronic intestinal diseases, including Crohn's disease (CD) and ulcerative colitis (UC). These diseases cause chronic inflammation of the intestinal mucosa and wall, leading to symptoms such as diarrhea, abdominal pain, constipation, fatigue, etc. Intestinal mucosal barrier can prevent microbial and other antigens enter the intestinal wall, maintain its healthy function. However, Immune system dysregulation, dysbiosis of the gut microbiome, and dysfunction of the intestinal epithelial barrier are key pathogenic mechanisms of IBD. The treatment of IBD remains an important medical challenge, the current treatment mainly by inhibiting immune activity, blocking certain inflammatory molecules. Although these methods can induce mucosal healing (MH), but infection and tumor adverse reactions associated with immunosuppression still need to solve. Therefore, researchers are exploring new treatments, to promote the healing of the intestinal mucosa and maintain intestinal health. This review summarizes the traditional treatment of IBD and the application of new technologies such as hydrogels, organoids, probiotics and prebiotics, which aim to safely and effectively promote mucosal barrier healing and restore intestinal function and balance.
Century Science Publishing Co
Title: Mucosal Healing Research Advances of Inflammatory Bowel Disease
Description:
Inflammatory bowel disease (IBD) refers to a group of chronic intestinal diseases, including Crohn's disease (CD) and ulcerative colitis (UC).
These diseases cause chronic inflammation of the intestinal mucosa and wall, leading to symptoms such as diarrhea, abdominal pain, constipation, fatigue, etc.
Intestinal mucosal barrier can prevent microbial and other antigens enter the intestinal wall, maintain its healthy function.
However, Immune system dysregulation, dysbiosis of the gut microbiome, and dysfunction of the intestinal epithelial barrier are key pathogenic mechanisms of IBD.
The treatment of IBD remains an important medical challenge, the current treatment mainly by inhibiting immune activity, blocking certain inflammatory molecules.
Although these methods can induce mucosal healing (MH), but infection and tumor adverse reactions associated with immunosuppression still need to solve.
Therefore, researchers are exploring new treatments, to promote the healing of the intestinal mucosa and maintain intestinal health.
This review summarizes the traditional treatment of IBD and the application of new technologies such as hydrogels, organoids, probiotics and prebiotics, which aim to safely and effectively promote mucosal barrier healing and restore intestinal function and balance.
Related Results
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
AbstractAim:Childhood onset inflammatory bowel disease is more aggressive and has rapidly progressive clinical course than adult inflammatory bowel disease. Early-onset inflammator...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
UNDERSTANDING HOW PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH
UNDERSTANDING HOW PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH
Abstract
BACKGROUND
Bowel urgency, the sudden or immediate need to have a bowel movement, is a burdensome symptom to patients wi...
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract
Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Abstract:
Background: ECF most frequently follows a complication of abdominal surgery, although a smaller number occur spontaneously in association with conditia
Background: Entero...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inf...

